Corcept Therapeutics sues over Teva generic Korlym label for alleged patented dosing method

Label wording for generic Korlym draws Corcept into court fight over patented dosing method

Corcept Therapeutics is asking a court to block Teva Pharmaceutical Industries from using proposed labeling for a generic version of Korlym, alleging the instructions would induce physicians to follow dosing methods that Corcept treats as its patented intellectual property. Corcept contends the label would effectively direct clinicians to co‑administer mifepristone with potent CYP3A inhibitors such as ketoconazole in specific combinations and dosing relationships that are covered by its method‑of‑use patents. The company argues that, even if the generic is chemically identical to Korlym, the content and dosing guidance in Teva’s label would encourage prescribing that infringes Corcept’s claims.

The dispute centers on the interplay between regulatory labeling, prescribing practice and patent enforcement in the pharmaceutical industry. Corcept says the contested label language goes beyond routine safety information and would steer medical practice toward the particular therapeutic strategy—pairing mifepristone with strong CYP3A inhibitors to manage drug exposure or enhance effect—that its patents protect. By seeking approval for a generic with that language, Teva is portrayed as potentially enabling third parties, including physicians, to implement the patented dosing regimen, creating a risk of induced infringement that Corcept is seeking to preempt through litigation.

Corcept frames its court action as protecting not only its patent portfolio but also the value of method‑of‑use rights that underpin investment in drug development. The company warns that allowing a generic label to serve as a vehicle for instructing clinicians in patented methods could weaken incentives for innovation and complicate how generics are labeled when method patents exist. Corcept seeks judicial relief to prevent the label’s use pending resolution, saying the outcome will shape prescribing behavior, generic competition and the enforcement landscape for method patents in endocrinology and related therapeutic areas.

Regulatory and commercial backdrop

Teva is pursuing approval of a generic Korlym as a lower‑cost alternative for patients with Cushing’s syndrome, and the case underscores tensions between expanding patient access through generic entry and protecting patented treatment regimens. How regulators respond to label language and how courts treat inducement claims will affect whether generic labeling can include dosing approaches that overlap with method patents.

Broader industry implications

Legal precedent from this dispute could influence future labeling negotiations between originators and generic applicants across the pharmaceutical industry, particularly where method‑of‑use patents exist for specific co‑administration strategies or dose relationships. Stakeholders say the decision may recalibrate how companies draft labels, seek approvals and litigate in cases where clinical practice intersects with patented methods.